- The Indian Patent Office rejected a patent application for a drug-resistant tuberculosis (TB) treatment regimen, preventing monopolistic pricing and ensuring cheaper generic availability. - The decision highlights the crucial balance between intellectual property rights (IPR) and public health access, particularly for life-saving drugs in developing nations. - Rejections under Indian patent laws often leverage provisions like Section 3(d) to prevent evergreening and protect affordable healthcare access. - **Indian Patents Act 1970:** The primary legislation governing patent law in India, enacted to encourage inventions and balance private monopoly rights with public health objectives and generic medicine availability. - **Section 3(d) of the Patents Act:** A key provision in India's patent law that prevents evergreening by requiring new forms of known substances to show significantly enhanced therapeutic efficacy before receiving patent protection. - **Indian Patent Office:** The statutory body under the Ministry of Commerce and Industry responsible for granting or rejecting patent applications in India according to national laws. **Introduction** The Indian Patent Office has rejected a patent application for a drug-resistant tuberculosis treatment regimen, a move hailed by public health advocates as a major victory for affordable healthcare and generic medicine accessibility in India and globally. **Core Issue and Detailed Points** - The Indian Patent Office rejected a patent application for a drug-resistant tuberculosis (TB) treatment regimen, preventing monopolistic pricing and ensuring cheaper generic availability. - The decision highlights the crucial balance between intellectual property rights (IPR) and public health access, particularly for life-saving drugs in developing nations. - Rejections under Indian patent laws often leverage provisions like Section 3(d) to prevent evergreening and protect affordable healthcare access. **Key Statutory Bodies, Acts & Concepts** - **Indian Patents Act 1970:** The primary legislation governing patent law in India, enacted to encourage inventions and balance private monopoly rights with public health objectives and generic medicine availability. - **Section 3(d) of the Patents Act:** A key provision in India's patent law that prevents evergreening by requiring new forms of known substances to show significantly enhanced therapeutic efficacy before receiving patent protection. - **Indian Patent Office:** The statutory body under the Ministry of Commerce and Industry responsible for granting or rejecting patent applications in India according to national laws.